Protocol Ledger

NCT05952804 · Phase II · RECRUITING

IVIG for Infection Prevention After CAR-T-Cell Therapy

Interventional Phase II clinical trial protocol NCT05952804 sponsored by Fred Hutchinson Cancer Center in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-10 Enrollment: 150 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05952804
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)150 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05952804
Protocol FieldVerified Registry Value
NCT IdentifierNCT05952804
Consolidated Lead SponsorFred Hutchinson Cancer Center
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment150 participants (ESTIMATED)
Registered Start Date2024-06-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fred Hutchinson / UW Medicine across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI